Answers are grounded in this paper and cite their sources.
Retrospective cohort analysis describes treatment patterns and costs in multiple myeloma, highlighting significant findings.
Background Multiple myeloma (MM) is the second most common hematologic malignancy worldwide. Despite therapeutic advances that have improved survival, MM treatment remains complex and costly, particularly across multiple lines of therapy. Real‐world data (RWD) from Latin America on MM care patterns and associated costs are limited. This study applied process mining techniques to analyze RWD from a Brazilian private insurer, aiming to describe treatment patterns and healthcare resource utilization. Methods This retrospective, observational study analyzed de‐identified administrative claims data from Unimed Paraná, Brazil, from 2014 to 2024. Eligible patients had ≥ 9 claims associated with the ICD‐10 code for multiple myeloma (C90.0) or recurrent use of MM‐specific therapies, including proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, bispecific antibodies, or CAR‐T cell therapy. This study describes a selected administrative‐claims cohort from a Brazilian private payer; therefore, findings should not be interpreted as representative of an incident MM population. Process mining was performed using UpFlux AI to identify care pathways and cost dynamics across treatment lines. Statistical analyses were conducted using R and GraphPad Prism, adopting a 5% significance level. Results A total of 68 patients were included (62% male; mean age 65.8 ± 11.1 years). Autologous stem cell transplantation (ASCT) was performed in 42.7% of cases. Twenty‐one therapeutic regimens were identified, most commonly those containing bortezomib, daratumumab, and lenalidomide. The mean total treatment cost per patient was USD 186350.83 (SD = 164645.73), with a mean annual cost of USD 78425.81. Descriptive differences in annual expenditures were observed between patients who initiated therapy in 2014–2019 and those in 2020–2024 (USD 57083.10 vs. USD 97397.11; p = 0.011). First‐line therapy accounted for 50% of total costs, followed by first‐line maintenance (25%). Mean monthly costs increased significantly with treatment complexity (single‐exposed: USD 3491.26; double‐exposed: USD 9504.87; triple‐exposed: USD 12796.55; p < 0.001). Conclusions RWD derived from process mining enabled a structured description of MM treatment pathways and associated costs within a Brazilian managed‐care context. Costs increased with treatment complexity, and variation in cost patterns was observed across treatment phases. Findings should be interpreted considering limitations inherent to claims‐based analyses, including lack of clinical detail and potential selection and immortal time bias.
No takes yet. Share an insight, caveat, or question.
RAMOS et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: